Lenvatinib shows promise for patients with radioiodine-refractory thyroid cancer
In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with ...
Feb 11, 2015
0
2